Does Rallies show Form 4 insider transactions for BDSX?

Yes. Rallies tracks BDSX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is BDSX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BDSX. It does not provide personalized investment advice.

BDSX (Biodesix, Inc. Common Stock) Stock Analysis - Insider Trades

Biodesix, Inc. Common Stock (BDSX) is a publicly traded Healthcare sector company. As of May 21, 2026, BDSX trades at $14.37 with a market cap of $144.05M and a P/E ratio of -3.06. BDSX moved +2.33% today. Year to date, BDSX is +130.66%; over the trailing twelve months it is +165.32%. Its 52-week range spans $3.44 to $36.00. Analyst consensus is strong buy with an average price target of $30.67. Rallies surfaces BDSX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading BDSX stock inside the company?

Recent BDSX insider activity includes Pestano Gary Anthony sold 556, O'Kane Kieran sold 535, Cowie Robin Harper sold 535, Vazquez Chris sold 211, and Hutton Scott sold 1.49K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

BDSX Key Metrics

Key financial metrics for BDSX
Metric	Value
Price	$14.37
Market Cap	$144.05M
P/E Ratio	-3.06
EPS	$-4.67
Dividend Yield	0.00%
52-Week High	$36.00
52-Week Low	$3.44
Volume	0
Avg Volume	0
Revenue (TTM)	$88.50M
Net Income	$-35.27M
Gross Margin	0.00%

Recent BDSX Insider Trades

Pestano Gary Anthony sold 556 (~$7.10K) on Feb 23, 2026.
O'Kane Kieran sold 535 (~$6.83K) on Feb 23, 2026.
Cowie Robin Harper sold 535 (~$6.83K) on Feb 23, 2026.
Vazquez Chris sold 211 (~$2.70K) on Feb 23, 2026.
Hutton Scott sold 1.49K (~$19.04K) on Feb 23, 2026.

Latest BDSX News

Biodesix to Present Real-World Clinical and Economic Nodify Lung Data at ATS May 15–20 — May 11, 2026
Biodesix Q1 Revenue Jumps 42% to $25.6M; Raises 2026 Guidance to $108–114M — May 4, 2026
Biodesix Named 2026 Top Workplace for 150+ Employees Third Year Running — Apr 9, 2026
Biodesix’s Nodify Test Shows 91-97% Specificity in 1,100-Patient Study — Mar 20, 2026
William Blair Upgrades Biodesix After Beats, Guides 23% Revenue Growth to $106–$112M — Feb 27, 2026

BDSX Analyst Consensus

5 analysts cover BDSX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.67.

Common questions about BDSX

Who is trading BDSX stock inside the company?: Recent BDSX insider activity includes Pestano Gary Anthony sold 556, O'Kane Kieran sold 535, Cowie Robin Harper sold 535, Vazquez Chris sold 211, and Hutton Scott sold 1.49K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for BDSX?: Yes. Rallies tracks BDSX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is BDSX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BDSX. It does not provide personalized investment advice.